High-dose aflibercept is in clinical development for the treatment of diabetic macular oedema. DMO is swelling of the macula caused by diabetes or by blockage of the veins behind the retina and it is the most common cause of sight loss in people with diabetes. DMO occurs when blood vessels damaged by high blood sugar leak into the central area of the retina (macula), a thin layer of tissue that lines the back of the eye, resulting in a fluid build-up. The risk of developing DMO is greater for people who have had diabetes for a long time, have poorly controlled blood sugar, have high blood pressure, have high cholesterol levels, smoke and are pregnant.
High-dose aflibercept for diabetic macular oedema
High-dose aflibercept is in clinical development for the treatment of diabetic macular oedema. DMO is swelling of the macula caused by diabetes or by blockage of the veins behind the retina and it is the most common cause of sight loss in people with diabetes.